One of the most prevalent cancers in the world is lung cancer. Various factors, multiple inherited, and acquired mechanisms contribute to lung carcinogenesis. The cholesterol-lowering medication atorvastatin (ATOR) has been demonstrated to have additional intriguing biological uses, such as anticancer effects. This study aimed to evaluate the effects of ATOR treatment against lung cancer in mice model. Forty-five male CD-1 mice were divided into 3 groups (n = 15) as the follows: Group 1 (G1) was used as a normal control. Gps 2 and 3 were administered with urethane (Ure) (1mg/g) and butylated hydroxytoluene (BHT) (200 mg/kg) for lung cancer initiation and promotion, respectively. G2 was left as a cancer-bearing group. G3 was post-treated with 10 mg/kg ATOR. The results showed that the treatment of Ure/BHT-administered mice with ATOR led to a significant decreased in the tumour incidences, multiplicities, and sizes as compared with each treatment alone. Further, the treatment with ATOR has significantly induced apoptosis in lung tumour cells without adverse side effects.